As known from:
CoinWireICOBenchCoinCodex
Write a Review
Write a Review
Nothing Found
Contains commercial content
TradersBest.com / Moderna Takes in $1.1 Billion in Deposits

Moderna Takes in $1.1 Billion in Deposits

Publish Date: 29/10/2020

Moderna has been preparing for a global launch to introduce their COVID-19 vaccine, as the American biotech company has already received over $1.1 billion dollars in deposits from a variety of different governments. The Cambridge, Massachusetts-based company has already been in talks with the World Health Organization. There have already been supply agreements made in principle in North AMerica, the Middle East and other regions around the world.

Moderna CEO Stephane Bancel recently stated in his press release that they are “actively preparing for the launch of mRNA-1273 and have agreed multiple supply agreements with governments around the world”. He went on to add that “Moderna is committed to the highest data quality standards and scientific research as we continue to work with regulators to advance mRNA-1273”. Moderna appears to have garnered more than enough interest in their potential COVID-19 vaccine, as countries try to find any way to resume some semblance of normalcy.

American Biotech Company on the Verge of Vaccine

Moderna has been preparing for a global launch to introduce their COVID-19 vaccine, as the American biotech company has already received over $1.1 billion dollars in deposits from a variety of different governments. The Cambridge, Massachusetts-based company has already been in talks with the World Health Organization. There have already been supply agreements made in principle in North AMerica, the Middle East and other regions around the world.

Moderna CEO Stephane Bancel recently stated in his press release that they are “actively preparing for the launch of mRNA-1273 and have agreed multiple supply agreements with governments around the world”. He went on to add that “Moderna is committed to the highest data quality standards and scientific research as we continue to work with regulators to advance mRNA-1273”. Moderna appears to have garnered more than enough interest in their potential COVID-19 vaccine, as countries try to find any way to resume some semblance of normalcy.

In what has essentially become a race for who can produce the Covid vaccine, Moderna are the clear frontrunners to do so. Moderna has already gathered 30,000 participants for their late-stage vaccine trials. As of last week, more than 25,650 participants had received the second of the company’s two-dose Covid-19 vaccine. As the mRNA-1273 vaccine has begun to build up a head of steam, so have the Moderna share prices which have risen by 2% in premarket trading value.

While the rise in share value of Moderna appears to be on an upward trend, the biotech company has had a rocky third-quarter. Analysts predicted that Moderna would see a loss of 43 cents per share but were off by 16 cents as the biotech company has lost 59 cents per share during a turbulent third-quarter. Overall, the company reported a $233.6 million third-quarter loss. However, despite the obvious difficulties of the financial year, Moderna still managed to walk away with $157.9 million in revenue outperforming what Wall Street believed would be a modest $77.5 million.

As it stands, the vaccine has not yet been released and Moderna have not only had a difficult third quarter but a difficult financial year overall. However, with supply agreements in place with a multitude of different countries there is certainly a share value peak coming for the American biotech firm. Analysts are already estimating that mRNA-1273 has an estimated peak forecast of $10.6B in 2026. The overall growth between 2021 – 2026 is expected to reach 2600%. As the demand for a Covid vaccine grows, it is becoming all the more certain that we will see significant growth in the value of Moderna shares in the months and years to come.

In what has essentially become a race for who can produce the Covid vaccine, Moderna are the clear frontrunners to do so. Moderna has already gathered 30,000 participants for their late-stage vaccine trials. As of last week, more than 25,650 participants had received the second of the company’s two-dose Covid-19 vaccine. As the mRNA-1273 vaccine has begun to build up a head of steam, so have the Moderna share prices which have risen by 2% in premarket trading value.

While the rise in share value of Moderna appears to be on an upward trend, the biotech company has had a rocky third-quarter. Analysts predicted that Moderna would see a loss of 43 cents per share but were off by 16 cents as the biotech company has lost 59 cents per share during a turbulent third-quarter. Overall, the company reported a $233.6 million third-quarter loss. However, despite the obvious difficulties of the financial year, Moderna still managed to walk away with $157.9 million in revenue outperforming what Wall Street believed would be a modest $77.5 million.

As it stands, the vaccine has not yet been released and Moderna have not only had a difficult third quarter but a difficult financial year overall. However, with supply agreements in place with a multitude of different countries there is certainly a share value peak coming for the American biotech firm. Analysts are already estimating that mRNA-1273 has an estimated peak forecast of $10.6B in 2026. The overall growth between 2021 – 2026 is expected to reach 2600%. As the demand for a Covid vaccine grows, it is becoming all the more certain that we will see significant growth in the value of Moderna shares in the months and years to come.

Read Also
Moderna Posts Strong Earnings Report With $7.2 Billion Revenues
Thursday saw Moderna posting its fourth-quarter earnings report which showed that the ...
US Stock Exchanges to Target Asian IPOs
The New York Stock Exchange and the Nasdaq are starting to target ...
Grab Makes Largest Stock Market Debut by South-East Asian Company
The Singapore start-up Grab made the largest stock-market debut ever by a ...
Twitter Stock Soars After CEO Quits
Yesterday saw Twitter CEO and founder Jack Dorsey quitting his role and ...
The Best NASDAQ stocks to watch in October 2021
The NASDAQ is an electronic marketplace for the buying and selling of ...
Latest News
Study: how do finances shape our love life?
Do we find someone less attractive if they're ...
Is FTX Bankrupt? 
The crypto market has seen a drastic change ...
Disney Shares Jump 6% After Positive Earnings Report
A booming subscriber base and the return of ...
Alibaba Posts Flat Revenue Growth But Stock Still Jumps 6%
Chinese ecommerce giant Alibaba posted its first earnings ...
Intel Stock Slumps Over 8% Following Weak Earnings Report
Chip-maker Intel suffered a disastrous end to last ...
Top Forex Sites
Ally Invest
Ally Invest
Ally Invest Review
4.8/5
Webull
Webull
Webull Review
4.6/5
Kraken
Kraken
Kraken Review
4.3/5
Nadex
Nadex Review
3.6/5
Interactive Brokers
Interactive Brokers Review
4.8/5
Receive the latest trading news by email + our free eBook
Crypto eBook EN
Nobody is born a trading expert. Register now to receive the Ultimate Guide to Trading Cryptocurrencies in 2022 (and beyond), and receive the TradersBest.com newsletter with the latest market news and broker reviews!.

By registering, I agree that TradersBest.com may send me newsletters via email at regular intervals. This consent can be revoked at any time.
Receive the latest trading news by email + our free eBook
Nobody is born a trading expert. Register now to receive the Ultimate Guide to Trading Cryptocurrencies in 2022 (and beyond), and receive the TradersBest.com newsletter with the latest market news and broker reviews!.

By registering, I agree that TradersBest.com may send me newsletters via email at regular intervals. This consent can be revoked at any time.
Trading financial products carries a high risk to your capital, especially trading leverage products such as CFDs.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Players must be 21 years of age or older or reach the minimum age for gambling in their respective state and located in jurisdictions where online gambling is legal. Please play responsibly. Bet with your head, not over it. If you or someone you know has a gambling problem, and wants help, call or visit: (a) the Council on Compulsive Gambling of New Jersey at 1-800-Gambler or www.800gambler.org; or (b) Gamblers Anonymous at 855-2-CALL-GA or www.gamblersanonymous.org.

Trading financial products carries a high risk to your capital, especially trading leverage products such as CFDs. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

This site is using Cloudflare and adheres to the Google Safe Browsing Program. We adapted Google's Privacy Guidelines to keep your data safe at all times.

21+NCPG
Close
×
Your Promo Code:
The bonus offer of was already opened in an additional window. If not, you can open it also by clicking the following link:
Visit Site